Anti-MGO-modified proteins 抗体 [MGO-1] (ab125158)
Key features and details
- Mouse monoclonal [MGO-1] to MGO-modified proteins
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG1
製品の概要
-
製品名
Anti-MGO-modified proteins antibody [MGO-1] -
製品の詳細
Mouse monoclonal [MGO-1] to MGO-modified proteins -
由来種
Mouse -
アプリケーション
適用あり: IHC-P, WBmore details -
種交差性
交差種: Human -
免疫原
MGO-modified proteins conjugated to KLH.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
バッファー
Preservative: 0.02% Sodium azide
Constituents: 0.1% BSA, 99% PBS -
Concentration information loading...
-
精製度
Protein G purified -
ポリ/モノ
モノクローナル -
クローン名
MGO-1 -
アイソタイプ
IgG1 -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab125158の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-P |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration.
|
特記事項 |
---|
IHC-P
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
ターゲット情報
-
関連性
Methylglyoxal (MGO) is an endogenous product of glucose metabolism. Increased production and accumulation of methylglyoxal (MGO), as well as increased modification of proteins by glycoxidation, are hallmarks of aging and diabetes. MGO was shown to modify proteins and to contribute to the accumulation of damaged proteins that can be toxic to cells. A number of studies have shown that MGO levels are significantly elevated in patients with Type 2 Diabetes and correlates well with fasting plasma glucose and hemoglobin A1c (HbA1c) levels. Moreover, increased formation of the MGO is implicated in renal dysfunction and is known to be involved in the development of DN (diabetic nephropathy).
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (0)
ab125158 は論文での使用が確認できていません。